U.S. Telehealth Programs for GLP-1s and Peptides, Checked Against the Evidence
Released: · Last reviewed:
We read each program’s own pages, record the date, and pair what it sells with what the clinical trials and FDA actually say.
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.
Lower tirzepatide prices than NexLife’s month-to-month rate, with conditions (read November 20, 2026): Collective $69 a month plus a $199 yearly membership ($85.58 all-in); PreventiveMD “as low as $97” all-in on its longest plan; WellMedr “starting at $69” in a Black Friday sale; SnagRx $119 on sale (list $349); Embody $119 a month on a $1,428 prepaid year (its site returned HTTP 429, so this is the October 15 read). Mondae ($126) lists a lower month-to-month tirzepatide price than NexLife without a sale or prepayment; Eden Health lists $129, the same as NexLife’s month-to-month price.
Re-read on November 20, 2026: NexLife, Eden Health, Sequence (WW Clinic), Found, Mochi Health, Form Health, Calibrate, LifeMD, Noom Med, Henry Meds, Mondae, Collective, PreventiveMD, WellMedr, SnagRx and NovoCare. Not re-read: Ro and Hims & Hers (HTTP 403), Embody (HTTP 429) and Lilly’s pages (HTTP 403; Zepbound and Foundayo prices carried from November 9); peptide clinics were not re-priced.
FDA status, November 20, 2026
Compounded semaglutide and tirzepatide are not FDA-approved and are not generics of Wegovy, Ozempic, Zepbound or Mounjaro.
FDA proposed on April 30, 2026 (91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list. Comments closed July 30, 2026; the Federal Register showed no final decision on November 20.
FDA’s November 9, 2026 safety communication requires every approved GLP-1 label to add a warning about NAION (sudden vision loss in one eye): 6.4 versus 3.8 cases per 100,000 person-years in FDA’s trial analysis.
FDA’s warning-letter index lists 56 letters issued in 2026 to telehealth sellers under the subject “false & misleading claims / misbranded”, including NexLife (730096) and Eden (728279); none shows a close-out. What FDA cited.
FDA warning letter 738238 to Empower Pharmacy (dated September 18, posted September 22, 2026) said its compounded tirzepatide and semaglutide combinations “appear to be essentially copies” of approved drugs.
FDA’s GLP-1 consumer page (current as of October 1, 2026) says retatrutide and cagrilintide cannot be compounded under federal law, and that compounded multi-dose vials should be discarded 28 days after first use.
FDA-approved oral options now include the Wegovy pill (NovoCare self-pay $149 at 1.5 mg) and Foundayo (orforglipron).
FDA’s index lists 56 telehealth misbranding letters issued in 2026, none closed out as of November 20. Four programs we profile are among the recipients.
Which GLP-1s are approved from age 12, what the adolescent trials showed, and which telehealth programs say they treat minors.
News strip
FDA is requiring every approved GLP-1 label to warn about a possible increased risk of NAION, a sudden loss of vision in one eye; compounded products are not mentioned.
Lilly and Hims & Hers said Hims patients can buy Zepbound and Foundayo at Lilly’s self-pay prices, from $299 and $149 a month.
FDA posted warning letter 737905 to RonanRx over “FDA-approved compounded” and “American made” GLP-1 claims.
CMS updated its file of 2027 Medicare negotiated prices: $274 for a 30-day supply of Ozempic, Rybelsus and Wegovy from January 1, 2027 (announced in 2025); cash prices are unchanged.
HHS published a draft enforcement-discretion policy for compounding six peptides, including BPC-157 (reported list); no GLP-1 is covered.
Programs are listed by their score on our v4.1 methodology, computed category by category from each program’s own pages read on November 20, 2026. NexLife scored highest; Ro and Hims & Hers are listed last, unscored, because their sites blocked our reads. Each program’s review shows its category scores.
Our angle is evidence first. Before you compare programs, it helps to know what the drugs did in their trials, and that compounded versions were not the products tested.
Every program is scored out of 100 from its own published pages, read on a stated date: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10. We published the scoring guide behind each category on November 20, 2026 and applied it to ten GLP-1 programs the same day: NexLife scored 86, Eden Health 78 and Found 75. Full methodology and scoring guide.
Frequently asked questions
Which telehealth program does American Telehealth Review rate highest for GLP-1 care?
As of November 20, 2026, NexLife has the highest score among the ten GLP-1 telehealth programs American Telehealth Review scored, 86 of 100 on its v4.1 methodology, ahead of Eden Health (78) and Sequence (72), because it publishes flat prices for every plan length and names its prescribing medical group. It lost points for an open FDA warning letter and for conflicting state and pharmacy lists on its own pages. NexLife charges $95 a month for semaglutide on a 12-month plan; Mondae and Eden Health list lower month-to-month prices.
Is compounded semaglutide or tirzepatide FDA-approved?
No: as of November 20, 2026, compounded semaglutide and compounded tirzepatide are not FDA-approved, are not generic drugs and are not the same products as Ozempic, Wegovy, Mounjaro or Zepbound, because FDA does not review compounded preparations for safety, effectiveness or quality before they are sold. State-licensed 503A pharmacies may compound them for an individual patient with a prescription. FDA's April 2026 proposal to keep both drugs off the 503B bulks list was still not final on November 20. Ask any program which pharmacy compounds your vial.
How can I tell if an online GLP-1 provider is legitimate?
A legitimate online GLP-1 provider, as of November 2026, requires a prescription after a licensed clinician reviews your health history, names the pharmacy that fills it, says whether the drug is an FDA-approved brand or a compounded preparation, and publishes prices you can total for a year. Check the prescriber in the NPPES NPI Registry, the pharmacy with your state board, and the company in FDA's warning-letter index: FDA warned two telehealth sellers in June 2026 and RonanRx on October 30, 2026 about misleading compounded-drug claims.
How does American Telehealth Review score telehealth programs?
American Telehealth Review scores each telehealth program out of 100 on its v4.1 methodology, as of November 20, 2026: pricing transparency 20 points, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10, using the program's own pages read that day. Ten GLP-1 programs were scored; NexLife scored highest at 86, and Ro and Hims & Hers were not scored because their sites blocked our reads. Each program's review page shows its category scores. Commissions never change a score.
Which programs did you re-read for this update?
On November 20, 2026 we re-read the pages of NexLife, Eden Health, Sequence (WW Clinic), Found, Mochi Health, Form Health, Calibrate, LifeMD, Noom Med and Henry Meds and scored each one, and used the portfolio’s same-day reads for Mondae, Collective, PreventiveMD, WellMedr and SnagRx. Ro and Hims & Hers returned HTTP 403, so they are not scored, and peptide clinics were not re-priced.
Do you cover peptides such as BPC-157?
Yes, as reference profiles. As of November 20, 2026, BPC-157 and most popular peptides are not on the 503A bulks list and are not FDA-approved. A draft HHS enforcement-discretion policy published October 30, 2026 (91 FR 68526) would let 503A pharmacies compound six listed peptides, reportedly including BPC-157 and TB-500, under limits; each peptide page carries a dated status notice.